ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Why is the PR still at 0.13 when there are so many PR's

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Mar 22, 2022 10:34pm

215 Views

Post# 34536485

RE:Why is the PR still at 0.13 when there are so many PR's

Easy answer look at the PR's. Vaccine 7 years out Two halt tradings over the last 7 years, private placements, someone point out another company that has done that? It's Eugene and Elliott that have mastered this, going to be interesting how this plays out, and Cashman will uptimately be responsible also. Does anyone know if there has been any blackouts with the BOD over potential deals or just talk?

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload